Market Overview on Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 - Pipeline Review, H2 2016

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted pipeline therapeutics.

The report provides comprehensive information on the Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)
- The report reviews key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics

Reasons to buy

- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Daiichi Sankyo Company, Limited Intellipharmaceutics International Inc. Mapi Pharma Ltd. Pfizer Inc. Prismic Pharmaceuticals, Inc. Yuhan Corporation

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###